Elsevier

Vaccine

Volume 41, Issue 9, 24 February 2023, Pages 1545-1549
Vaccine

Short communication
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine

https://doi.org/10.1016/j.vaccine.2023.01.049Get rights and content

Highlights

  • •

    This prospective cohort study assessed immune response to the BNT162b vaccine.

  • •

    Participants were followed up from pre-vaccination to 6 months after the 3rd dose.

  • •

    Immunity 6 months after the 3rd dose was similar to that 8 weeks after the 2nd dose.

  • •

    The 3rd dose produced a more durable immune response than the 2nd dose.

Abstract

Longitudinal data on the immune response from the first dose to several months after the third dose of COVID-19 vaccine are limited. We analyzed the immune response in 406 Japanese healthcare workers who received at least three doses of vaccine. The geometric mean anti-receptor binding domain IgG antibody titers and antigen-stimulated T-cell interferon-gamma levels after 6 months after receiving a third dose were similar to those 8 weeks after receiving a second dose. Humoral and cellular immunity induced by the third dose was more durable than that induced by the second dose.

UMIN Clinical Trials Registry ID: UMIN000043340.

Keywords

COVID-19 vaccine
BNT162b2
Third dose
Antibody
Cellular immunity

Data availability

Data will be made available on request.

Cited by (0)

View Abstract
© 2023 Elsevier Ltd. All rights reserved.